Nemolizumab: First Approval

被引：49

作者：

Keam, Susan J. ^{[1
]}

机构：

[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand

来源：

DRUGS | 2022年 / 82卷 / 10期

关键词：

T-CELLS; INTERLEUKIN-31; RECEPTOR; DERMATITIS; PRURITUS; CYTOKINE; TRIAL; IL-31; SKIN;

D O I：

10.1007/s40265-022-01741-z

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Nemolizumab is a subcutaneously administered humanized anti-interleukin-31 (IL-31) receptor A (IL-31RA) monoclonal antibody that is being developed by Chugai Pharmaceutical Co. Ltd, Maruho Co. Ltd and Galderma Pharma S.A. for the treatment of skin diseases, including atopic dermatitis (AD), AD associated pruritus (ADaP), prurigo nodularis (PN), chronic kidney disease associated pruritus (CKDaP) and systemic sclerosis (SSc). IL-31 is a neuroimmune cytokine that induces itch, inflammation, keratinocyte differentiation and fibroblast activation in chronic pruritic skin diseases. Nemolizumab (Mitchga(R) Syringes) was approved in Japan on 28 March 2022 for use in adults and children over the age of 13 years for the treatment of itch associated with AD (only when existing treatment is insufficiently effective). This article summarizes the milestones in the development of nemolizumab leading to this first approval.

引用

页码：1143 / 1150

页数：8

共 32 条

[1]

Chugai Pharmaceutical, 2016, CHUG GALD ANN GLOB L

[2] Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice [J].

Dillon, SR ;

Sprecher, C ;

Hammond, A ;

Bilsborough, J ;

Rosenfeld-Franklin, M ;

Presnell, SR ;

Haugen, HS ;

Maurer, M ;

Harder, B ;

Johnston, J ;

Bort, S ;

Mudri, S ;

Kuijper, JL ;

Bukowski, T ;

Shea, P ;

Dong, DL ;

Dasovich, M ;

Grant, FJ ;

Lockwood, L ;

Levin, SD ;

LeCiel, C ;

Waggie, K ;

Day, H ;

Topouzis, S ;

Kramer, J ;

Kuestner, R ;

Chen, Z ;

Foster, D ;

Parrish-Novak, J ;

Gross, JA .

NATURE IMMUNOLOGY, 2004, 5 (07) :752-760

[3] Interleukin-31 and Pruritic Skin [J].

Furue, Masutaka ;

Furue, Mihoko .

JOURNAL OF CLINICAL MEDICINE, 2021, 10 (09)

[4]

Galderma, 2021, GALD ANN NEW DAT DEM

[5]

Galderma, 2022, GALD ANN POS DAT PHA

[6] Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies [J].

Kabashima, K. ;

Matsumura, T. ;

Komazaki, H. ;

Kawashima, M. .

BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) :642-651

[7] Interleukin-31 as a Clinical Target for Pruritus Treatment [J].

Kabashima, Kenji ;

Irie, Hiroyuki .

FRONTIERS IN MEDICINE, 2021, 8

[8] Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus [J].

Kabashima, Kenji ;

Matsumura, Takayo ;

Komazaki, Hiroshi ;

Kawashima, Makoto .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (02) :141-150

[9] Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study [J].

Kabashima, Kenji ;

Furue, Masutaka ;

Hanifin, Jon M. ;

Pulka, Grazyna ;

Wollenberg, Andreas ;

Galus, Ryszard ;

Etoh, Takafumi ;

Mihara, Ryosuke ;

Nakano, Miwa ;

Ruzicka, Thomas .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 142 (04) :1121-+

[10] Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis [J].

Kato, Atsuhiko ;

Fujii, Etsuko ;

Watanabe, Takeshi ;

Takashima, Yoshiaki ;

Matsushita, Hiroaki ;

Furuhashi, Takuya ;

Morita, Akimichi .

JOURNAL OF DERMATOLOGICAL SCIENCE, 2014, 74 (03) :229-235

← 1 2 3 4 →